Clinical Trial Update: In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating the safety and potential benefit of adding Lutetium-177 PSMA radioligand therapy to chemotherapy in men with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-naive Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (Pluvicto) (lutetium-177 PSMA-617)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Metastatic Hormone Naive Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING